hypereosinophilic syndrome
hypereosinophilic syndrome
Explore linked clinical trials. Standard reference: MONDO:001569137 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07323654 | |
| Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Recruiting | Phase 2 | 2026-10-06 | NCT06477653 | |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05692180 | |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Active, not recruiting | Phase 4 | 2026-09-25 | NCT03953300 | |
| Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma | Bacterial Infections and Mycoses, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Infections, Respiratory Hypersensitivity, allergic bronchopulmonary aspergillosis, aspergillosis, fungal infectious disease, fungal lung infectious disease, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, pulmonary aspergilloma, pulmonary eosinophilia, respiratory system disorder, respiratory tract infectious disorder | Not yet recruiting | Not applicable | 2026-09-24 | NCT07828327 | |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Eosinophilia, Granuloma, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, asthma, autoimmune disease, bronchial disorder, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, obstructive lung disease, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 3 | 2026-09-22 | NCT07444567 | |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Not stated | 2026-09-18 | NCT07214753 | |
| A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Recruiting | Not stated | 2026-09-16 | NCT00091871 | |
| Fasenra: An Asthma Study | Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Enrolling by invitation | Phase 4 | 2026-09-15 | NCT07654842 | |
| Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Recruiting | Phase 3 | 2026-09-04 | NCT05334368 | |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hepatomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, liver disorder | Active, not recruiting | Phase 2 | 2026-09-01 | NCT03801434 | |
| A Non-interventional, Prospective Study With Benralizumab | Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Recruiting | Not stated | 2026-08-28 | NCT06422078 | |
| A Study of Depemokimab in Participants of 6 to 11 Years of Age | Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 3 | 2026-08-26 | NCT07671001 | |
| REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM) | Airway Remodeling, Eosinophilia, Hemic and Lymphatic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Not yet recruiting | Not applicable | 2026-07-31 | NCT07174713 | |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Chronic Disease, Disease Attributes, Eosinophilia, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acquired polycythemia vera, acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cellular phase chronic idiopathic myelofibrosis, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, hypereosinophilic syndrome, leukemia, leukocyte disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, myeloid neoplasm, myeloproliferative neoplasm, myeloproliferative neoplasm, unclassifiable, neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-16 | NCT03862157 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Active, not recruiting | Phase 3 | 2026-07-10 | NCT04191304 | |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 3 | 2026-05-13 | NCT06750289 | |
| Mepolizumab and Physical Activity in Severe Asthma | Dyspnea, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Hypersensitivity, Signs and Symptoms, Signs and Symptoms, Respiratory, asthma, bronchial disorder, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder | Active, not recruiting | Not stated | 2026-04-24 | NCT05404763 | |
| Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma | Eosinophilia, Hemic and Lymphatic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, nasal cavity polyp, nasal disorder, otorhinolaryngologic disease, polyp, pulmonary eosinophilia, respiratory system disorder | Active, not recruiting | Not stated | 2026-04-17 | NCT06069310 | |
| SIM0718 Treatment of Asthma Clinical Study | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 3 | 2026-04-02 | NCT06488755 | |
| Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-03-16 | NCT00044304 | |
| Natural History of Hypereosinophilia and Hypereosinophilic Syndromes | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Recruiting | Not stated | 2026-02-20 | NCT04018118 | |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA | Eosinophilia, Granuloma, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, asthma, autoimmune disease, bronchial disorder, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Enrolling by invitation | Phase 4 | 2026-01-15 | NCT07343661 | |
| The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome | Eosinophilia, Granuloma, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Not applicable | 2025-12-10 | NCT07275190 | |
| A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Not yet recruiting | Phase 2 | 2025-11-26 | NCT07250594 |